Navigation Links
Kinase Inhibitors Market to Reach $11.6 Billion in US, $40.3 Billion Globally by 2016
Date:7/10/2012

FARMINGTON, Conn., July 10, 2012 /PRNewswire-iReach/ -- More companies are investing in kinase inhibitor research to address issues such as resistance, selectivity versus safety, developing lead compounds, and integrating chemistry and biology into development, as well as utilizing the latest technologies and techniques such as fragment- and structure-based design to develop new products. Having accurate market data and analysis is essential to companies that wish to compete on the global stage. With premium market research from the world's leading publishers, Global Information Inc. helps businesses stay on the cutting edge with the best forecasts, research, and analyses.

(Photo: http://photos.prnewswire.com/prnh/20120710/CG37789)

Global Information is pleased to announce the immediate availability of three significant new reports on Kinase Inhibitors.

Kinase Inhibitors: Global Markets -- Focus on Europe

Kinase Inhibitors: Global Markets -- Focus on US

Kinase Inhibitors: Global Markets -- Focus on Emerging Markets

The overall goal of this series is to provide a comprehensive understanding of the current and future characteristics for kinase inhibitors, which include tyrosine inhibitors, multi-target kinase inhibitors, serine/threonine inhibitors and monoclonal antibody kinase inhibitors.

Each report offers market sizes with sales and revenues figures from 2011 to 2016 for kinase inhibitors in the pharmaceutical and biotechnology industry. Market projections, market shares and a technology SWOT analysis are also included.

Global revenues for kinase inhibitors were nearly $29.1 billion in 2011 and are projected to reach nearly $40.3 billion in 2015 at a five-year compound annual growth rate (CAGR) of 6.7%. The kinase inhibitors market is witnessing an increasing number of novel kinase inhibitors being utilized in human trials, particularly in the development of next-generation inhibitors that target cancers and other disease, including inflammation.

The United States kinase inhibitor market accounted for $10.4 billion in 2011 and is expected to reach $11.6 billion by 2016 at a CAGR of 2.2%. Monoclonal antibody kinase inhibitors in the U.S. market brought in $7.6 billion in 2010 and came down to $6.6 billion in 2011. This segment is expected to continue on a downward trend at a CAGR of -4% to reach $5.4 billion in 2016.

Strong growth is expected in the emerging markets segment for kinase inhibitors, which reached $2.9 billion in 2010 and $4.1 billion in 2011 and is expected to post $8.4 billion by 2016 at a CAGR of 15.2%. Antibody kinase inhibitors in the emerging markets segment is expected to reach $4.3 billion by 2016.

An Executive Summary of this analysis and a free sample of each report is available from Global Information, Inc:

Emerging Markets
http://www.giiresearch.com/report/bc246348-kinase-inhibitors-global-markets-focus-on-emerging.html

US Markets
http://www.giiresearch.com/report/bc246349-kinase-inhibitors-global-markets-focus-on-us.html

European Markets
http://www.giiresearch.com/report/bc246350-kinase-inhibitors-global-markets-focus-on-europe.html

BCC Research provides a multitude of studies on the Biotechnology markets. Topics range from stem cells to enzyme inhibitors and drug discovery technologies. Each report analyzes the market along with its applications, regulatory environment, technology, market projections and market share. Discover more at http://www.giiresearch.com/publisher/BC/biotechnology.shtml

About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

Media Contact: Jeremy Palaia Global Information, Inc., 1-860-674-8796, Press@gii.co.jp  

News distributed by PR Newswire iReach: https://ireach.prnewswire.com



'/>"/>
SOURCE Global Information, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
2. Global Angiogenesis Inhibitors and Stimulators Industry
3. Global Markets for Enzyme Inhibitors
4. Emerging Markets for Enzyme Inhibitors Surge, To Grow More Than 50% by 2016
5. United States Market for Psoriatic Arthritis Pharmacotherapy
6. Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
7. Analysis of the North American Radiology Image and Information Management Systems Market
8. Sports Medicine Implants Market - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
9. North America ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
10. Middle East and Africa Surgical Equipment Market Outlook to 2018 -Electrosurgical Devices, Hand Instruments and Surgical Sutures
11. Medical Diagnostic & Therapeutic Ultrasound Devices Market (2012 - 2017) - Global Trends & Competitive Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
Breaking Medicine Technology:
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
Breaking Medicine News(10 mins):